image
Healthcare - Medical - Care Facilities - NASDAQ - US
$ 0.18
-23.5 %
$ 13.6 M
Market Cap
-0.23
P/E
1. INTRINSIC VALUE

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.[ Read More ]

The intrinsic value of one TOI stock under the base case scenario is HIDDEN Compared to the current market price of 0.18 USD, The Oncology Institute, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TOI

image
FINANCIALS
324 M REVENUE
28.42%
-77 M OPERATING INCOME
-6.96%
-83.1 M NET INCOME
-5013.16%
-36.3 M OPERATING CASH FLOW
41.20%
62.6 M INVESTING CASH FLOW
147.59%
-6.85 M FINANCING CASH FLOW
-7.43%
99.9 M REVENUE
1.34%
-13.9 M OPERATING INCOME
15.34%
-44.9 M NET INCOME
-190.25%
-30.1 M OPERATING CASH FLOW
-91.93%
47.7 M INVESTING CASH FLOW
162.25%
-3.33 M FINANCING CASH FLOW
-55.01%
Balance Sheet Decomposition The Oncology Institute, Inc.
image
Current Assets 143 M
Cash & Short-Term Investments 82.9 M
Receivables 42.9 M
Other Current Assets 17.7 M
Non-Current Assets 65.7 M
Long-Term Investments 0
PP&E 40.1 M
Other Non-Current Assets 25.7 M
Current Liabilities 34.8 M
Accounts Payable 14.4 M
Short-Term Debt 6.36 M
Other Current Liabilities 14 M
Non-Current Liabilities 117 M
Long-Term Debt 113 M
Other Non-Current Liabilities 4.12 M
EFFICIENCY
Earnings Waterfall The Oncology Institute, Inc.
image
Revenue 324 M
Cost Of Revenue 265 M
Gross Profit 59.6 M
Operating Expenses 137 M
Operating Income -77 M
Other Expenses 6.05 M
Net Income -83.1 M
RATIOS
18.37% GROSS MARGIN
18.37%
-23.75% OPERATING MARGIN
-23.75%
-25.62% NET MARGIN
-25.62%
-145.67% ROE
-145.67%
-39.70% ROA
-39.70%
-53.52% ROIC
-53.52%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis The Oncology Institute, Inc.
image
Net Income -83.1 M
Depreciation & Amortization 5.87 M
Capital Expenditures -4.57 M
Stock-Based Compensation 17.8 M
Change in Working Capital 2.36 M
Others 27 M
Free Cash Flow -40.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets The Oncology Institute, Inc.
image
TOI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership The Oncology Institute, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
348 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
127 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
9 months ago
Jan 29, 2024
Sell 18.3 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 8637
2.12 USD
9 months ago
Jan 24, 2024
Sell 57.3 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 24915
2.3 USD
9 months ago
Jan 25, 2024
Sell 24.6 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 11882
2.07 USD
9 months ago
Jan 26, 2024
Sell 14.9 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 6979
2.14 USD
9 months ago
Jan 19, 2024
Sell 25.5 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 11986
2.13 USD
9 months ago
Jan 22, 2024
Sell 21.8 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 10263
2.12 USD
9 months ago
Jan 23, 2024
Sell 11.3 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 5338
2.11 USD
11 months ago
Dec 14, 2023
Bought 706 USD
Shah Mihir
Chief Financial Officer
+ 565
1.25 USD
11 months ago
Dec 14, 2023
Bought 126 K USD
Shah Mihir
Chief Financial Officer
+ 99435
1.27 USD
1 year ago
Nov 17, 2023
Sell 56 K USD
Hively Brad
Director
- 25000
2.24 USD
1 year ago
Nov 13, 2023
Sell 119 K USD
Hively Brad
Director
- 47000
2.523 USD
1 year ago
Mar 17, 2023
Bought 5.5 K USD
BARASCH RICHARD A
Director
+ 10000
0.55 USD
1 year ago
Mar 17, 2023
Bought 5.5 K USD
BARASCH RICHARD A
Director
+ 10000
0.55 USD
1 year ago
Mar 17, 2023
Bought 1.18 K USD
BARASCH RICHARD A
Director
+ 2146
0.548 USD
1 year ago
Mar 17, 2023
Bought 4.21 K USD
BARASCH RICHARD A
Director
+ 7654
0.55 USD
1 year ago
Mar 17, 2023
Bought 5.47 K USD
BARASCH RICHARD A
Director
+ 9948
0.55 USD
1 year ago
Mar 17, 2023
Bought 110 USD
BARASCH RICHARD A
Director
+ 200
0.548 USD
1 year ago
Mar 17, 2023
Bought 28.5 USD
BARASCH RICHARD A
Director
+ 52
0.549 USD
1 year ago
Mar 17, 2023
Bought 5.5 K USD
BARASCH RICHARD A
Director
+ 10000
0.55 USD
1 year ago
Dec 16, 2022
Bought 70 K USD
Miller Matthew P
Chief Operating Officer
+ 73684
0.95 USD
2 years ago
Nov 15, 2022
Sell 7.64 K USD
Virnich Daniel
President
- 3767
2.0278 USD
2 years ago
Nov 15, 2022
Sell 385 USD
Simoneit Diona
Chief Accounting Officer
- 190
2.0278 USD
2 years ago
Nov 15, 2022
Sell 404 USD
Podnos Yale
Chief Medical Officer
- 199
2.0277 USD
2 years ago
Nov 15, 2022
Sell 1.17 K USD
Miller Matthew P
Chief Operating Officer
- 577
2.0277 USD
2 years ago
Nov 15, 2022
Sell 19.7 K USD
Hively Brad
Chief Executive Officer
- 9718
2.0278 USD
2 years ago
Nov 11, 2022
Sell 851 K USD
Havencrest Healthcare Partners, L.P.
Director
- 365321
2.33 USD
2 years ago
Nov 14, 2022
Sell 34.1 K USD
Kaushal Mohit
Director
- 15994
2.131 USD
2 years ago
Nov 08, 2022
Sell 87.5 K USD
Havencrest Healthcare Partners, L.P.
Director
- 27000
3.24 USD
2 years ago
Nov 09, 2022
Sell 247 K USD
Havencrest Healthcare Partners, L.P.
Director
- 80000
3.09 USD
2 years ago
Nov 10, 2022
Sell 183 K USD
Havencrest Healthcare Partners, L.P.
Director
- 61281
2.98 USD
2 years ago
Nov 03, 2022
Sell 163 K USD
Havencrest Healthcare Partners, L.P.
Director
- 45500
3.58 USD
2 years ago
Nov 04, 2022
Sell 170 K USD
Havencrest Healthcare Partners, L.P.
Director
- 50200
3.39 USD
2 years ago
Nov 07, 2022
Sell 62.9 K USD
Havencrest Healthcare Partners, L.P.
Director
- 19167
3.28 USD
2 years ago
Oct 31, 2022
Sell 196 K USD
Havencrest Healthcare Partners, L.P.
Director
- 41855
4.69 USD
2 years ago
Nov 01, 2022
Sell 214 K USD
Havencrest Healthcare Partners, L.P.
Director
- 50272
4.26 USD
2 years ago
Nov 02, 2022
Sell 230 K USD
Havencrest Healthcare Partners, L.P.
Director
- 58500
3.94 USD
2 years ago
Oct 26, 2022
Sell 271 K USD
Havencrest Healthcare Partners, L.P.
Director
- 52500
5.16 USD
2 years ago
Oct 27, 2022
Sell 178 K USD
Havencrest Healthcare Partners, L.P.
Director
- 35000
5.09 USD
2 years ago
Oct 28, 2022
Sell 252 K USD
Havencrest Healthcare Partners, L.P.
Director
- 52091
4.84 USD
2 years ago
Oct 21, 2022
Sell 99.2 K USD
Havencrest Healthcare Partners, L.P.
Director
- 20000
4.96 USD
2 years ago
Oct 24, 2022
Sell 146 K USD
Havencrest Healthcare Partners, L.P.
Director
- 29400
4.98 USD
2 years ago
Oct 25, 2022
Sell 155 K USD
Havencrest Healthcare Partners, L.P.
Director
- 30400
5.1 USD
2 years ago
Oct 24, 2022
Sell 23.8 K USD
Kaushal Mohit
Director
- 4798
4.96 USD
2 years ago
Oct 18, 2022
Sell 56.5 K USD
Havencrest Healthcare Partners, L.P.
Director
- 12200
4.63 USD
2 years ago
Oct 19, 2022
Sell 81.9 K USD
Havencrest Healthcare Partners, L.P.
Director
- 17500
4.68 USD
2 years ago
Oct 20, 2022
Sell 58 K USD
Havencrest Healthcare Partners, L.P.
Director
- 12000
4.83 USD
2 years ago
Oct 13, 2022
Sell 118 K USD
TOI HC I, LLC
Director
- 25200
4.67 USD
2 years ago
Oct 14, 2022
Sell 44.5 K USD
TOI HC I, LLC
Director
- 9800
4.54 USD
2 years ago
Oct 17, 2022
Sell 37.9 K USD
TOI HC I, LLC
Director
- 8249
4.6 USD
2 years ago
Oct 10, 2022
Sell 93.1 K USD
TOI HC I, LLC
Director
- 21500
4.33 USD
2 years ago
Oct 11, 2022
Sell 116 K USD
TOI HC I, LLC
Director
- 25000
4.66 USD
2 years ago
Oct 12, 2022
Sell 67.4 K USD
TOI HC I, LLC
Director
- 14343
4.7 USD
2 years ago
Oct 05, 2022
Sell 67.2 K USD
TOI HC I, LLC
Director
- 14060
4.78 USD
2 years ago
Oct 06, 2022
Sell 149 K USD
TOI HC I, LLC
Director
- 33509
4.45 USD
2 years ago
Oct 07, 2022
Sell 67.8 K USD
TOI HC I, LLC
Director
- 14652
4.63 USD
2 years ago
Sep 30, 2022
Sell 51.5 K USD
TOI HC I, LLC
Director
- 11000
4.68 USD
2 years ago
Oct 03, 2022
Sell 79.1 K USD
TOI HC I, LLC
Director
- 16765
4.72 USD
2 years ago
Oct 04, 2022
Sell 114 K USD
TOI HC I, LLC
Director
- 23447
4.85 USD
2 years ago
Sep 27, 2022
Sell 66 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 14074
4.69 USD
2 years ago
Sep 28, 2022
Sell 59.7 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 12642
4.72 USD
2 years ago
Sep 29, 2022
Sell 97 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 21000
4.62 USD
2 years ago
Sep 22, 2022
Sell 55.6 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 13086
4.25 USD
2 years ago
Sep 23, 2022
Sell 22.5 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 5375
4.19 USD
2 years ago
Sep 26, 2022
Sell 32.7 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 7153
4.57 USD
2 years ago
Sep 15, 2022
Sell 312 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 68500
4.55 USD
2 years ago
Sep 16, 2022
Sell 900 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 200000
4.5 USD
2 years ago
Sep 19, 2022
Sell 85 K USD
Havencrest Healthcare Partners, L.P.
10 percent owner
- 19629
4.33 USD
2 years ago
Sep 12, 2022
Sell 210 K USD
Havencrest Healthcare Partners, L.P.
Director
- 38000
5.52 USD
2 years ago
Sep 12, 2022
Sell 277 K USD
Havencrest Healthcare Partners, L.P.
Director
- 52500
5.28 USD
2 years ago
Sep 12, 2022
Sell 189 K USD
Havencrest Healthcare Partners, L.P.
Director
- 37785
4.99 USD
2 years ago
Sep 07, 2022
Sell 110 K USD
TOI HC I, LLC
director:
- 18900
5.8 USD
2 years ago
Sep 01, 2022
Sell 252 K USD
TOI HC I, LLC
director:
- 41783
6.03 USD
2 years ago
Aug 29, 2022
Sell 92.1 K USD
TOI HC I, LLC
director:
- 15000
6.14 USD
2 years ago
Aug 24, 2022
Sell 21.9 K USD
TOI HC I, LLC
director:
- 3525
6.2 USD
2 years ago
Aug 19, 2022
Sell 232 K USD
TOI HC I, LLC
director:
- 35500
6.53 USD
2 years ago
Aug 12, 2022
Sell 104 K USD
TOI HC I, LLC
director:
- 16663
6.23 USD
2 years ago
Jun 10, 2022
Sell 1.54 M USD
Jimmy Holdings, Inc.
director:
- 300000
5.15 USD
2 years ago
May 11, 2022
Sell 1.52 M USD
Jimmy Holdings, Inc.
director:
- 253435
6 USD
2 years ago
Nov 24, 2021
Bought 8.64 K USD
BARASCH RICHARD A
Director
+ 1200
7.2022 USD
2 years ago
Nov 24, 2021
Bought 12.3 K USD
BARASCH RICHARD A
Director
+ 1800
6.858 USD
2 years ago
Nov 24, 2021
Bought 13.6 K USD
BARASCH RICHARD A
Director
+ 2000
6.8088 USD
2 years ago
Nov 23, 2021
Bought 28.6 K USD
BARASCH RICHARD A
Director
+ 4500
6.348 USD
2 years ago
Nov 23, 2021
Bought 3.13 K USD
BARASCH RICHARD A
Director
+ 500
6.2667 USD
3 years ago
Nov 16, 2021
Bought 10.1 K USD
BARASCH RICHARD A
Director
+ 1000
10.115 USD
3 years ago
Nov 12, 2021
Bought 50 M USD
Flynn James E
Director
+ 50000
1000 USD
7. News
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. seekingalpha.com - 3 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc. NEW YORK, NY / ACCESSWIRE / November 8, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc. NEW YORK, NY / ACCESSWIRE / November 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology NEW YORK, NY / ACCESSWIRE / November 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc. NEW YORK, NY / ACCESSWIRE / November 5, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 week ago
The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). globenewswire.com - 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology NEW YORK, NY / ACCESSWIRE / November 4, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc. NEW YORK, NY / ACCESSWIRE / November 1, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 2 weeks ago
Constellation Software Inc. and Topicus.com Inc. Announce Results for Topicus.com Inc. for the Third Quarter Ended September 30, 2024 TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the third quarter ended September 30, 2024. Please note that all amounts referred to in this press release are in Euros unless otherwise stated. globenewswire.com - 2 weeks ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc NEW YORK, NY / ACCESSWIRE / October 31, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 2 weeks ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc. NEW YORK, NY / ACCESSWIRE / October 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 2 weeks ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute Inc. NEW YORK, NY / ACCESSWIRE / October 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 2 weeks ago
8. Profile Summary

The Oncology Institute, Inc. TOI

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 13.6 M
Dividend Yield 0.00%
Description The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Contact 18000 Studebaker Road, Cerritos, CA, 90703 https://theoncologyinstitute.com
IPO Date June 4, 2020
Employees 800
Officers Mr. Richard Alan Barasch Chairman of the Board Dr. Daniel Virnich FACHE, M.B.A., M.D. Chief Executive Officer & Executive Director Mr. Mark Hueppelsheuser Esq. General Counsel Ms. Laura Szitar Chief People Officer Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. Chief Medical Officer Mr. Jeremy N. Castle M.B.A. Chief Operations Officer Mr. Jordan McInerney Chief Development Officer Mr. Rob Carter Chief Financial Officer